A Phase 1b trial of specific immunotherapy for recurrent respiratory papillomatosis

复发性呼吸道乳头状瘤病特异性免疫疗法的 1b 期试验

• 批准号: nhmrc : 142902
• 负责人: Prof Ian Frazer
• 金额: $ 9.42万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2001
• 资助国家: 澳大利亚
• 起止时间: 2001-01-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phase-1b-trial-respiratory-papillomatosis/99998
• 关键词: Phase; 1b; trial; specific; immunotherapy

This project will determine whether immunisation can be used to effectively treat an existing infection. To date, immunisation has only been used to prevent infection, but there are many chronic infections where intervention might help the body's defences to to a better job and clear the chronic infection. In this study, we will work out whether this approach can be applied to a virus infection ( papillomavirus) which is associated with cancer. We will test immunisation against a chronic and lifethreatening disorder in which warts grow in the respirarory tract, as there is currently no satisfactory treatment for this. If the project is successful we may also learn which blood tests are likely to predict the outcome of immunisation to treat infection.

该项目将确定免疫接种是否可以有效地治疗现有的感染。到目前为止，免疫接种只用于预防感染，但在许多慢性感染中，干预可能有助于身体的防御，以更好地工作并清除慢性感染。在这项研究中，我们将研究这种方法是否适用于与癌症相关的病毒感染(乳头瘤病毒)。我们将测试针对一种慢性和危及生命的疾病的免疫接种，在这种疾病中，疣在呼吸道中生长，因为目前还没有令人满意的治疗方法。如果该项目成功，我们还可能了解到哪些血液测试可能预测免疫接种治疗感染的结果。